abs435.txt	introduction	the	rising	cost	of	cancer	drugs	may	make	treatment	unaffordable	forsome	patients		often	rely	on	drug	manufacturer-administeredpharmaceutical	assistance	programs	(paps)	to	obtain	and	reduced	or	no	overall	usage	paps	within	care	delivery	is	unknown	methods	weincluded	all	across	an	academically	affiliated	integrated	healthsystem	in	north	carolina	during	2014	(	n	=	8591)	we	identified	subset	ofpatients	receiving	pap	afford	one	more	order	tocalculate	proportion	retailvalue	results	among	8591	215	unique	patientssubmitted	a	total	478	successful	requests	for	40%	ofpap-utilizing	were	uninsured	23%	had	medicaid	coverage	20%	hadmedicare	2%	dual	medicare/medicaid	eligible	14%	werecommercially	insured	who	received	medical	6	0%	required	whereas	10	6%	oral	agent	papassistance	varied	substantially	by	ranging	from	<1%	(e	g	carboplatin	methotrexate)	50%	patients(e	ponatinib	temsirolimus)	majority	retail	value	obtained	was	fororal	agents	including	$1	556	575	imatinib	449	633	dasatinib	whichwere	two	with	highest	aggregate	conclusions	asubstantial	receive	private	charitable	assistanceto	standard-of-care	treatments	this	includes	federal	andprivate	insurance	suggesting	inability	meet	cost-sharingrequirements
